Mural Oncology
Waltham
About Mural Oncology
Mural Oncology is an independent public company. Mural Oncology would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the company's portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted split interleukin-12 (IL-12) and interleukin-18 (IL-18).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Total funding: $275.0M
- Funding stage: M&A
- Last round: Corporate Round (Nov 2023)
- Ticker: nasdaq:MURA
- Website: muraloncology.com
Industries & Categories
Health Care, Oncology, Public Relations, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mural-oncology-96763 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.